Pierre A. MORGON is Chief Executive Officer of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement, an evergreen investment structure focused on medical devices, in vitro diagnostics and patient management services.
He is also Chairman of the Board of Virometix since January 2017, a company developing proprietary synthetic nanoparticle platform in vaccines and immunotherapeutic drugs for viral diseases and cancer, as well as Non-Executive Director to the Board of Theradiag since March 2012, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy, and Non-Executive Director to the Board of Eurocine Vaccines since December 2013, a company dedicated to developing nasal vaccines. He joined the board of Virometix as chairman in January 2017
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs.
Pierre has over 30 years of experience in the global pharmaceutical and biological industry and in healthcare IT, at the helm of operations and in global staff positions up to C-level. Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets segments, geographies and organizations.
Specifically in the vaccine industry, Pierre has performed in C-level roles in large corporations and start-up companies as well as through board positions. He also piloted the acquisition of the production and commercialization business of the Statens Serum Institute by the AlJomaih group. In these positions, he has demonstrated mastery with the construction and expansion of vaccine portfolio and partnerships, with turnaround initiatives and with financing for start-up vaccine companies.
Through the combined perspective and firsthand experience of the vaccine industry executive, of the board member and of the investor, Pierre brings expertise in the design and execution of portfolio strategy, the design of R&D, manufacturing strategy and the piloting of the return on invested capital, and the crafting and valuation of business development and partnering activities along the entire value chain.
In addition, Pierre is recognized for his seminal articles addressing the commercialization of vaccines and vaccine innovation and value creation and he is a frequent speaker in vaccine conferences. He has been distinguished as one of the top 50 most influential vaccine personalities by World Vaccine Congress in 2013.